Samama M, Nguyen G, Desnoyers P, Lourenco D M, Fretault J, Horellou M H, Conard J, Szwarcer E, Verdy E, Vahanian A
Laboratoire Central d'Hématologie, Hôpital Tenon, Paris, France.
Fundam Clin Pharmacol. 1988;2(6):509-23. doi: 10.1111/j.1472-8206.1988.tb00652.x.
Thrombolytic, fibrinolytic, and fibrinogenolytic properties of tissue plasminogen activator (t-PA) from melanoma cells (mt-PA), recombinant t-PA (rt-PA), streptokinase (SK), single-chain urokinase plasminogen activator (scu-PA), and high and low molecular weight urokinase (HMW UK, LMW UK) were compared in vitro by means of systems using human plasma. Thrombolytic activities were tested on standard or labeled hanging clots. When compared on the basis of urokinase international units, t-PA appeared to be slightly more active than scu-PA and streptokinase, and about 10-fold more active than both preparations of UK when they were diluted in plasma. Fibrinolytic activity was evaluated by measuring the lysis time of recalcified plasma containing variable amounts of thrombolytic agents. t-PA was shown to be twice as active as HMW UK, which was itself more active than LMW UK. When scu-PA and both types of UK were compared on bovine fibrin plates, they showed similar fibrinolytic activity, but the t-PA calibration curve was not parallel to those obtained with UK and scu-PA. Relative thrombolytic and fibrinogenolytic properties were studied for each thrombolytic agent. For similar thrombolytic activities, fibrinogenolysis provoked by scu-PA was less marked than with t-PA and with both UK, while SK showed the highest activity. Our results demonstrate that the thrombolytic/fibrinogenolytic ratio is much more favorable to t-PA and scu-PA than to both forms of UK. Another observation clearly shows that fibrinogenolysis can be induced in vitro in human plasma by high doses of t-PA. This consequence may be important since the therapeutic use of t-PA can be associated with high concentrations of t-PA, and thus t-PA infusion could lead in vivo to severe fibrinogen breakdown. In addition, the methodology described could be useful in standardizing comparison between different species of thrombolytic agents.
通过使用人血浆的系统,在体外比较了黑色素瘤细胞组织纤溶酶原激活剂(mt-PA)、重组t-PA(rt-PA)、链激酶(SK)、单链尿激酶型纤溶酶原激活剂(scu-PA)以及高分子量和低分子量尿激酶(HMW UK、LMW UK)的溶栓、纤维蛋白溶解和纤维蛋白原溶解特性。在标准或标记的悬垂凝块上测试溶栓活性。以尿激酶国际单位为基础进行比较时,t-PA似乎比scu-PA和链激酶的活性略高,当它们在血浆中稀释时,其活性比两种尿激酶制剂高约10倍。通过测量含有不同量溶栓剂的重新钙化血浆的溶解时间来评估纤维蛋白溶解活性。结果显示t-PA的活性是HMW UK的两倍,而HMW UK本身比LMW UK更具活性。当在牛纤维蛋白平板上比较scu-PA和两种类型的尿激酶时,它们显示出相似的纤维蛋白溶解活性,但t-PA校准曲线与尿激酶和scu-PA的校准曲线不平行。研究了每种溶栓剂的相对溶栓和纤维蛋白原溶解特性。对于相似的溶栓活性,scu-PA引起的纤维蛋白原溶解比t-PA和两种尿激酶引起的要轻,而链激酶显示出最高活性。我们的结果表明,溶栓/纤维蛋白原溶解比对于t-PA和scu-PA比对于两种形式的尿激酶更有利。另一个观察结果清楚地表明,高剂量的t-PA可在体外诱导人血浆中的纤维蛋白原溶解。这一结果可能很重要,因为t-PA的治疗应用可能与高浓度的t-PA相关,因此t-PA输注可能在体内导致严重的纤维蛋白原分解。此外,所描述的方法学可能有助于标准化不同种类溶栓剂之间的比较。